KLK3 and prostate cancer: When fusion transcripts, leukocyte genome LSR and Nomogram were combined, it improved the outcomes of prostate cancer prediction to 58.1% PSA-free survival if they were predicted to be non-recurrent by the model versus 16.9% if they were predicted as likely recurrent by the combined model (p = 2.9x10-6 for the two survival curves).